Shared from the live wire
中位 OS 較含鉑雙藥化療延長 8.5 個月(25.9 vs 17.4 個月)，死亡風險降低 31%(HR 0.69；95% CI 0.54–0.89；單側 P = 0.0021)。 兩年 OS 率為 54.1% vs 37.2%，提高 16.9 %；中位隨訪 32.3 個月，生存獲益持續。 校正後中位 OS 相差 9.3 個月(25.9 vs 16.6 個月)：采用預設的 RPSFT 模型進行後續 ADC 治療校正後，死亡風險降低 43%(HR 0.57；95% CI 0.42–0.75)。 成都2026年10月25日 /美通社/ --...
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Free plan · Plus CA$29 or Pro CA$99/month
Governments, regulators, central banks, companies and the newswires — in one live screen, searchable, filterable, and watching what you track.
01
Live, not a digest
Every release the moment it crosses — no daily email, no 24-hour lag.
02
Alerts on what you track
Save a search and know the instant a matching release lands.
03
The whole archive
Search back through every release by country, sector, source and language.
1,400+ feeds — live on PPN World right now
Releases like this one land on PPN World as they are published, from 190+ countries. Read the next one first.
Create free account →Free plan · Plus CA$29 or Pro CA$99/month
Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →
